Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 4, 1997, Pages 179-186

  Snyder, David S ^a   Wu, Yaping ^a   McMahon, Ross ^a   Yu, Lijuan ^a   Rossi, John J ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; p190 bcr abl; Philadelphia chromosome; Ribozymes

Indexed keywords

BCR ABL PROTEIN; RIBOZYME;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CELL CULTURE; CELL DIVISION; DRUG EFFECT; ENZYME SPECIFICITY; ENZYME STABILITY; GENE EXPRESSION; GENETICS; HUMAN; HYDROLYSIS; ONCOGENE; PATHOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL DIVISION; ENZYME STABILITY; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; HYDROLYSIS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; ONCOGENES; RNA, CATALYTIC; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0031241407     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON: Expression of a distinctive bcr-abl oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 239:775, 1988.
2. Maurer J, Janssen JWG, Thiel E, Van Denderen J, Ludwig W-D, Aydemir U, Heinze B, Fonatsch C, Harbott J, Reiter A, Riehm H, Hoelzer D, Bartram CR: Detection of chimeric bcr-abl genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 337:1055, 1991.
3. Suryanarayan K, Hunger SP, Kohler S, Carroll AJ, Crist W, Link MP, Cleary ML: Consistent involvement of BCR gene by 9;22 breakpoints in pediatric acute leukemias. Blood 77:324, 1991.
4. Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgstrom GH, Brandt L, Catovsky D, de la Chapelle A, Dewald GW, Garson OM, Garwicz S, Golomb HM, Hossfeld DK, Lawler SD, Mitelman F, Nilsson P, Pierre RV, Philip P, Prigogina E, Rowley JD, Sakurai M, Sandberg AA, Secker-Walker LM, Tricot G, Van den Berghe H, Van Orshoven A, Vuopio P, Whang-Peng J: Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 67:415, 1986.
5. Fletcher JA, Lynch EA, Kimball VM, Donnelly M, Tantravahi R, Sallan SE: Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 77:435, 1991.
6. Stockschlader M, Hegewisch-Becker S, Kruger W, tom Dieck A, Mross K, Hoffknecht M, Berger C, Kohlschutter B, Martin H, Peters S, Kabisch H, Kuse R, Weh H, Zander A: Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 16:663, 1995.
7. Dunlop LC, Powles R, Singhal S, Treleaven JG, Swansbury GJ, Meller S, Pinkerton CR, Horton C, Mehta J: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplantation 17:365, 1996.
8. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JWG, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Sschaub G, Bartram CR, Ludwig W-D, Riehm H, Lampert F, Harbott J: Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 10:957, 1996.
9. Martin H, Atta J, Zumpe P, Eder M, Elsner S, Rode C, Wassmann B, Bruecher J, Hoelzer D: Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia. Exp Hematol 23:1612, 1995.
10. Atta J, Martin H, Bruecher J, Elsner S, Wassmann B, Rode C, Russ A, Kvalheim G, Hoelzer D: Residual leukemia and immunomagnetic bead purging in patients with BCR-ABL-positive acute lymphoblastic leukemia. Bone Marrow Transplant 18:541, 1996.
11. Garcia J, Punti C, Picon M, Tigues D, Amill B, Canals C, Ayats R, Ramon I, Gilabert R, Sierra J, Badell I, Brunet S, Ortega J, Valls A, Granena A: Bone marrow purging in acute lymphoblastic leukemia: biological and clinical features. J Hematother 3:203, 1994.
12. Gehly GB, Bryant EM, Lee AM, Kidd PG, Thomas ED: Chimeric BCR-abl RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 78:458, 1991.
13. Gewirtz AM: Bone marrow purging with antisense oligodeoxynucleotides. Prog Clin Biol Res 377:215, 1992.
14. Gewirtz AM: Therapeutic applications of antisense DNA in the treatment of human leukemia. Ann NY Acad Sci 660:178, 1992.
15. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B: Selective inhibition of leukemia cell proliferation by bcr-abl antisense oligodeoxynucleotides. Science 253:562, 1991.
16. Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szczylik C, Chen S-T, Lange B, Calabretta B: Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr-abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 92:194, 1993.
17. De Fabritiis P, Amadori S, Calabretta B, Mandelli F: Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 12:261, 1993.
18. Thomas M, Kosciolek B, Wang N, Rowley P: Capping of bcr-abl anti-sense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines. Leuk Res 18:401, 1994.
19. Maekawa T, Kimura S, Hirakawa K, Murakami A, Zon G, Abe T: Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligodeoxynucleoside phosphorothioates. Int J Cancer 62:63, 1995.
20. Chasty R, Whetton A, Lucas G: A comparison of the effect of bcr-abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr-abl positive and negative, CD34 enriched mononuclear cell populations. Leuk Res 20:391, 1996.
21. Rowley PT, Keng PC, Kosciolek BA: The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells. Leuk Res 20:473, 1996.
22. Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B: Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr-abl antisense oligodeoxynucleotides. JNCI 89:124, 1997.
23. Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM: Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 79:1956, 1992.
24. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gewirtz AM: In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89:11823, 1992.
25. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M: BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but non-antisense mechanism. Blood 86:3891, 1995.
26. Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J: Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 23:1606, 1995.
27. Smetsers TFCM, Linders EHP, van de Locht LTF, De Witte TM, Mensink EJBM: An antisense BCR-ABL phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism. Br J Haematol 96:377, 1997.
28. Cech TR, Bass BL: Biological catalysis by RNA. Ann Rev Biochem 55:599, 1986.
29. Koizumi M, Hayase Y, Iwai S, Kamiya H, Inoue H, Ohtsuka E: Design of RNA enzymes distinguishing a single base mutation in RNA. Nucl Acids Res 17:7059, 1989.
30. Pyle AM: Ribozymes: a distinct class of metalloenzymes. Science 261:709, 1993.
31. Scott WG, Klug A: Ribozymes: structure and mechanism in RNA catalysis. Trends Biochem Sci 21:220, 1996.
32. Bertrand E, Pictet R, Grange T: Can hammerhead ribozymes be efficient tools to inactivate gene function? Nucleic Acids Res 22:293, 1994.
33. Butcher SE, Burke JM: A photo-cross-linkable tertiary structure motif found in functionally distinct RNA molecules is essential for catalytic function of the hairpin ribozyme. Biochem 33:992, 1994.
34. Butcher SE, Burke JM: Structure-mapping of the hairpin ribozyme. Magnesium-dependent folding and evidence for tertiary interactions within the ribozyme-substrate complex. J Mol Biol 244:52, 1994.
35. Butcher SE, Heckman JE, Burke JM: Reconstitution of hairpin ribozyme activity following separation of functional domains. J Biol Chem 270:29648, 1995.
36. Burke JM: Hairpin ribozyme: Current status and future prospects. Biochem Soc Trans 24:608, 1996.
37. Celander DW, Cech TR: Visualizing the higher order folding of a catalytic RNA molecule. Science 251:401, 1991.
38. Schmidt S, Beigelman L, Karpeisky A, Usman N, Sorensen US, Gait MJ: Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure. Nucleic Acids Res 24:573, 1996.
39. Shin C, Choi JN, Sang SI, Song JT, Ahn JH, Lee JS, Choi YD: The loop B domain is physically separable from the loop A domain in the hairpin ribozyme. Nucleic Acids Res 24:2685, 1996.
40. Altman S: RNA enzyme-directed gene therapy. Proc Natl Acad Sci USA 90:10898, 1993.
41. Rossi JJ: Therapeutic antisense and ribozymes. Br Med Bull 51:217, 1995.
42. Kiehntopf M, Esquivel EL, Brach MA, Herrmann F: Ribozymes: biology, biochemistry, and implications for clinical medicine. Clin Investig 73:65, 1995.
43. Kiehntopf M, Esquivel EL, Brach MA, Herrmann F: Clinical applications of ribozymes. Lancet 345:1027, 1995.
44. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 55:2024, 1995.
45. Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ: Therapeutic applications of ribozymes. Pharmacol Ther 68:247, 1995.
46. Eastham JA, Ahlering TE: Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line. J Urol 156:1186, 1996.
47. Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82:600, 1993.
48. Shore SK, Nabissa PM, Reddy EP: Ribozyme-mediated cleavage of the BCR-ABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Oncogene 8:3183, 1993.
49. Pachuk CJ, Yoon K, Moelling K, Coney LR: Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences. Nucleic Acids Res 22:301, 1994.
50. Lange W, Daskalakis M, Finke J, Dolken G: Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Letters 338:175, 1994.
51. Lange W, Cantin EM, Finke J, Dolken G: In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7:1786, 1993.
52. Leopold LH, Shore SK, Newkirk TA, Reddy RMV, Reddy EP: Multiunit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 85:2162, 1995.
53. Kearney P, Wright LA, Milliken S, Biggs JC: Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA. Exp Hematol 23:986, 1995.
54. Kronenwett R, Haas R, Sczakiel G: Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J Mol Biol 259:632, 1996.
55. James HA, Twomey CM, Mills KI, Gibson I: Specificity of ribozymes against the bcr-abl mRNAs in vitro. Biochem Soc Trans 24:4095, 1996.
56. Sane DC, Chema DJ: PCR-based production of a ribozyme to plasminogen activator inhibitor-1. Biotechniques 18:208, 1995.
57. Sioud M, Natvig JB, Forre O: Preformed ribozyme destroys tumor necrosis factor mRNA in human cells. J Mol Biol 223:831, 1992.
58. Guo JQ, Lian JY, Xian YM, Lee M-S, Deisseroth AB, Stass SA, Champlin RE, Talfaz M, Wang JYJ, Arlinghaus RB: BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 83:3629, 1994.
59. Brenner MK, Heslop HE, Rill D, Li C, Nilson T, Roberts M, Smith C, Krance R, Rooney C: Gene transfer and bone marrow transplantation. Cold Spring Harbor Symp Quant Biol 59:691, 1994.
60. Brenner MK, Rill DR, Moen RC, Krance RA, Heslop HE, Mirro J Jr, Anderson WF, Ihle JN: Gene marking and autologous bone marrow transplantation. Ann NY Acad Sci 716:204, 1994.
61. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Andersson B, Claxton D: Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: a pilot trial. Hum Gene Ther 2:359, 1991.
62. Ciccarone V, Anderson D, Lan J, Schifferli K, Jessee J: DMRIE-C reagent for transfection of suspension cells and for RNA transfections. Focus 17:84, 1995.